Q3 Earnings Forecast for FATE Issued By HC Wainwright

Fate Therapeutics, Inc. (NASDAQ:FATE) – Equities research analysts at HC Wainwright issued their Q3 2026 earnings per share (EPS) estimates for Fate Therapeutics in a report released on Friday, October 31st. HC Wainwright analyst R. Burns forecasts that the biopharmaceutical company will earn ($0.32) per share for the quarter. HC Wainwright has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for Fate Therapeutics’ current full-year earnings is ($1.63) per share. HC Wainwright also issued estimates for Fate Therapeutics’ Q4 2026 earnings at ($0.33) EPS and FY2026 earnings at ($1.27) EPS.

Fate Therapeutics (NASDAQ:FATE) last announced its quarterly earnings data on Tuesday, August 12th. The biopharmaceutical company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.06. The firm had revenue of $1.91 million for the quarter, compared to analyst estimates of $1.16 million. Fate Therapeutics had a negative return on equity of 50.95% and a negative net margin of 2,025.05%.

FATE has been the topic of several other reports. Cantor Fitzgerald reiterated a “neutral” rating on shares of Fate Therapeutics in a research report on Tuesday. Wedbush upgraded Fate Therapeutics from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $5.00 to $7.00 in a research report on Monday, October 27th. Wells Fargo & Company reduced their price objective on Fate Therapeutics from $4.00 to $2.50 and set an “equal weight” rating on the stock in a research report on Wednesday, August 13th. Wall Street Zen raised Fate Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, August 18th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Fate Therapeutics in a research note on Monday, October 27th. Three analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $3.92.

Fate Therapeutics Trading Down 5.6%

Shares of Fate Therapeutics stock opened at $1.19 on Monday. The firm has a market capitalization of $137.24 million, a PE ratio of -0.82 and a beta of 2.42. The business’s 50-day moving average price is $1.22 and its 200-day moving average price is $1.19. Fate Therapeutics has a 12 month low of $0.66 and a 12 month high of $3.50.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Savant Capital LLC bought a new position in shares of Fate Therapeutics during the second quarter valued at about $27,000. Bridgeway Capital Management LLC purchased a new stake in shares of Fate Therapeutics during the second quarter worth about $28,000. CWM LLC lifted its holdings in Fate Therapeutics by 899.6% in the 1st quarter. CWM LLC now owns 41,435 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 37,290 shares during the period. Caption Management LLC purchased a new stake in Fate Therapeutics in the 1st quarter worth approximately $45,000. Finally, Jane Street Group LLC lifted its holdings in Fate Therapeutics by 106.9% in the 1st quarter. Jane Street Group LLC now owns 63,691 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 32,911 shares during the period. 97.54% of the stock is owned by institutional investors.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.